The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
512
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level
Time frame: Week 8
Percentage of patients achieving LDL goal at 2 and 4 weeks
Time frame: Weeks 2 and 4
Lipid changes at week 4 & 8
Time frame: Weeks 4 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São José, Santa Catarina, Brazil
Pfizer Investigational Site
São Paulo, SP/Brazil, Brazil
Pfizer Investigational Site
Campinas, São Paulo, Brazil
Pfizer Investigational Site
Campinas, São Paulo, Brazil
Pfizer Investigational Site
São José do Rio Preto, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
...and 23 more locations